New Broker Ratings For ZIOPHARM Oncology Inc (ZIOP)

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for ZIOPHARM Oncology Inc as 1.51 Million.

4 analysts are covering ZIOPHARM Oncology Inc (ZIOP) and their average rating on the stock is 2.5, which is read as a Buy.

In an overview of the current analyst recommendations, Buy count is 1 and Overweight is 0 while the number of analysts recommending Sell and Underweight are 0 and 0, respectively.

The stock is now trading at Distance from 20-Day simple moving Average of -2.89% whereas, Distance from 50-Day Simple moving average is -1.27 Percent and Distance from 200-Day Simple Moving Average of -26.1 percent.

Receive ZIOPHARM Oncology Inc News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc with's FREE daily email newsletter. ZIOPHARM Oncology Inc opened at $5.12 and closed at $5.13 by showing an increase of 2.34%. It has total market capitalization of $1.01B. The company has market value of $669.44M. 1 of the brokerages firms have a buy or better rating; the 0 sells versus 0 underperforms. The stock stands almost $9.81 off versus the 52-week high of $14.93 and $0.67 above the 52-week low of $4.45. (NASDAQ:AUPH) traded higher 1.94% in last trading session to close the day at a price $2.1/share.

Over the past five trading sessions shares of ZIOPHARM Oncology, Inc. Year to Date performance value (YTD perf) value is -36.82%. The stock hit the peak price level of one year at $18.40 and touched the minimum level of $4.98.

Historically the stock has climbed 0.14% in the past week and soared 0.29% in the last four weeks, the stock illustrate that its three months performance stands at -0.28% while its year to date performance is at -27.63%.

The Relative Volume of the company is 0.76 and Average Volume (3 months) is 2.21 million. The company will report its next earnings on Oct 31 - Nov 4 (Est.).

The company has its Return on Assets (ROA) of -114.5 Percent.

While looking at the Stock's Performance, ZIOPHARM Oncology Inc now shows a Weekly Performance of 1.35%, where Monthly Performance is 7.8%, Quarterly performance is -26.16%, 6 Months performance is -40.07% and yearly performance percentage is -43.18%.

For the second quarter of 2016, Sarepta reported a net loss of $62.3 million, or $1.35 per share, compared to a net loss of $41.9 million for the second quarter of 2015, or $1.01 per share. The stock has received "HOLD" rating after consensus analysis from analysts.

Earnings Roundup: In the last fiscal quarter alone, ZIOPHARM Oncology, Inc. generated almost $1.7M in sales. (NASDAQ:ZIOP) are 1.35%; 7.8% for the month; -26.16% for the last quarter; -40.07% for the past six-months; and -43.18% for the last 12 months.The current price is staying below the SMA lines which signify weakens and is generally unhealthy/negative and may provide the momentum for driving the share price lower.

  • Arturo Norris